bioRxivImmunology
A novel multi-epitope peptide vaccine candidate targeting Hepatitis E virus: an in-silico approach
Abstract
HEV is a foodborne virus transmitted through the fecal-oral route that causes viral hepatitis in humans worldwide. Ever since its discovery as a zoonotic agent, HEV was isolated from several species with an expanding range of hosts. HEV possesses several features of other RNA viruses but also has certain HEV-specific traits that make its viral-host interactions inimitable. HEV leads to severe morbidity and mortality in immunocompromised people and pregnant women across the world. The situation in underdeveloped countries is even more alarming. Even after creating a menace across the world, we still lack an effective vaccine against HEV. Till date, there is only one licensed vaccine for HEV available only in China. The development of an anti-HEV vaccine that can reduce HEV-induced morbidity and mortality is required. Live attenuated and killed vaccines against HEV are not accessible due to the lack of a tolerant cell culture system, slow viral replication kinetics and varying growth conditions. Thus, the main focus for anti-HEV vaccine development is now on the molecular approaches. In the current study, we have designed a multi-epitope vaccine against HEV through a reverse vaccinology approach (Figure 1). For the first time, we have used viral ORF3, capsid protein and polyprotein altogether for epitope prediction. These are crucial for viral replication and persistence and are major vaccine targets against HEV. The proposed in-silico vaccine construct comprises of highly immunogenic and antigenic T-cell and B-cell epitopes of HEV proteins and ORF3. The construct is capable of inducing an effective and long-lasting host immune response as evident from the simulations results. In addition, the construct is stable, non-allergic and antigenic for the host. Altogether, our findings suggest that the in-silico vaccine construct may be useful as a vaccine candidate for preventing HEV infections. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=164 SRC="FIGDIR/small/520355v1_fig1.gif" ALT="Figure 1"> View larger version (44K): org.highwire.dtl.DTLVardef@354f48org.highwire.dtl.DTLVardef@1e80119org.highwire.dtl.DTLVardef@a04ed5org.highwire.dtl.DTLVardef@97bab0_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 1:C_FLOATNO An overview of multi-epitope vaccine construct designing using different in-silico tools. C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inferring B-cell derived T-cell receptor induced multi epitope-based vaccine candidate against enterovirus 71 (EV 71): A reverse vaccinology approach.
S. Panda, S. K. Swain, … R. Sarangi·bioRxiv·Mar 4, 2023
- The Endocytic Recycling Compartment Serves as a Viral Factory for Hepatitis E Virus
C. Bentaleb, K. Hervouet, … L. Cocquerel·bioRxiv·Oct 14, 2021
- Development of a Pan-Proteome Multi-Epitope Vaccine Candidate Against Nipah Virus Using Reverse Vaccinology and Immunoinformatics Approaches
Rasel Khan Nishan, Md. Nahian, … Md. Shariful Islam·bioRxiv·Nov 6, 2026
- Characterization of the hepatitis E virus replicase
K. Metzger, B. Cyrine, … C. M. Aliouat Denis·bioRxiv·Dec 3, 2021
- Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health
S. Srivastava, S. Verma, … M. Kolbe·bioRxiv·Sep 17, 2021
- Epitope-based peptide vaccine against glycoprotein G of Nipah henipavirus using immunoinformatics approaches
Arwa A. Mohammed, Shaza Wagiealla Shantier, … Mohamed Ahmed Salih Hassan·Journal of Immunology ResearchPeer-reviewed·Jan 1, 2020